Researchers have uncovered a previously unknown gene that causes resistance to a leading blood cancer drug, as well as several genes that accelerate lymphoma growth, using a powerful new CRISPR activation library.

Researchers at DZNE and Charité—Universitätsmedizin Berlin are working on a targeted therapy for neurological autoimmune diseases. So far, they have successfully tested their approach in mouse studies involving two such conditions. Their concept is based on deliberately modified immune cells, so-called CAAR T cells, designed to eliminate only the immune cells responsible for causing disease.

Scientists have long believed that large stretches of our genetic material, known as long noncoding RNAs (lncRNAs), help regulate genes but do not produce proteins. A new study by Stav Zok and Professor Michal Linial from the Hebrew University of Jerusalem suggests that this picture is incomplete.

A research team led by Professor Zhou Xuyu from the Institute of Microbiology of the Chinese Academy of Sciences (CAS), in collaboration with researchers from Beijing Ditan Hospital and Capital Medical University, has identified ANKRD11 as a key regulator that reduces the activity of CD8+ T cells during chronic hepatitis B virus (HBV) infection and cancer. The researchers found that ANKRD11 suppresses the AP-1 signaling pathway, which usually helps CD8+ T cells mount effective responses against infections and tumors.

A scientist at Cincinnati Children’s who has hunted for decades for ways to shrink the painful and disfiguring nerve tumors caused by neurofibromatosis type 1 (NF1) has made a new breakthrough in the quest.

Researchers from the University of California San Diego and collaborators have identified a previously overlooked pattern of DNA mutations in colorectal cancer. Scientists use these patterns, known as mutational signatures, to investigate the biological and environmental processes that have damaged DNA during cancer development.

Every RNA virus—from stomach bugs and influenza to measles and the common cold—has its own story to tell, with a unique combination of symptoms, transmission rates, duration and chemical blueprint.

MIT researchers’ approach, which uses naturally occurring sugars as antifreeze, could make it easier for hospitals to deploy this type of cancer treatment.

A new stem cell treatment for ARK (aniridia-related keratopathy) improved patients’ vision in a first-in-human clinical trial for this previously untreatable rare genetic eye condition at Moorfields Eye Hospital and University College London (UCL), published in JAMA Ophthalmology.